Introduction {#Sec1}
============

Background {#Sec2}
----------

Vesicourethral anastomotic stenosis (VUAS) is an uncommon complication post radical prostatectomy. However, in intractable cases, urinary retention and possible management options can be problematic for both surgeons and patients. Current literature estimates the incidence of VUAS to be between 1 and 26% \[[@CR1]--[@CR4]\]. This wide range in incidence is likely due to the evolution of prostatectomy technique from open surgery to robot assisted. In 2007, the CaPSURE study of 3310 men found an incidence of VUAS in 8.4% post radical prostatectomy (RP) \[[@CR1]\]. More recent studies of VUAS post robot-assisted radical prostatectomy (RARP) have shown a risk of VUAS of 1.4% \[[@CR2]\]. However, salvage robot-assisted radical prostatectomy (sRARP) post radiotherapy or brachytherapy has shown an incidence rate between 22 and 26% \[[@CR3], [@CR4]\].

The goals of VUAS treatment include resolving urinary retention, maintaining continence and achieving good physiological voiding. First-line treatment is endoscopic dilation, internal urethrotomy or transurethral resection of the stricture area. Depending on the number of attempts of these treatments, patency rates can vary from 17 to 89% \[[@CR5]--[@CR7]\]. In the case of intractable VUAS, treatment options include injection of mitomycin C with dilation resulting in patency rates of 79% for the first procedure and 86% for a secondary procedure \[[@CR8]\]. Further treatment options include bladder neck reconstruction, with patency rates of 60--80% \[[@CR9]\] or urinary diversion options such as long-term urethral or suprapubic catheters, vesicostomy or ileal conduit formation. Whilst surgical reconstruction and urinary diversion are associated with better patency rates compared to endoscopic treatments, complication rates, erectile function, continence and patient satisfaction are worse \[[@CR10], [@CR11]\].

Aims {#Sec3}
----

With the aim of providing superior patency, safety and quality outcomes, we retrospectively reviewed 30 patients managed with the nickel--titanium, thermo-expandable Memokath^®^045 stent as an alternative treatment approach to manage intractable VUAS.

Hypothesis {#Sec4}
----------

The use of the Memokath^®^045 stent in patients with VUAS will provide superior quality of life, flow and incontinence outcomes than current treatment options.

Materials and methods {#Sec5}
=====================

Patients {#Sec6}
--------

We retrospectively reviewed 30 patients, with an age range of 50--73. They all had a Memokath^®^045 stent insertion following two previous failed endoscopic dilations following VUAS. The median time from RP to Memokath^®^045 insertion was 13 months. All procedures were performed at two sites (University College London Hospital and The London Clinic), by two surgeons (SN and GM).

Memokath^®^045 stent {#Sec7}
--------------------

The stent is a spiral thermo-expandable nickel--titanium alloy shaped like an hour-glass. The structure is part flexible and part rigid, the result is a thermosensitive 'shape memory'. The advantage is that a deformed piece of alloy can be restored to its original shape. The alloy softens at temperatures below 7--13 °C and returns to a preformed shape when warmed to a temperature above 55 °C. Furthermore, these stents have a tight spiral structure, which prevents urothelial in-growth between the coils. Its spiral construction allows the Memokath^®^045 stent to conform and adapt to the natural curves of the urinary tract. The resulting lack of outward pressure minimizes the risk of secondary ischemic injury to the urothelium. Furthermore, its titanium component resists corrosion in the urinary tract. The internal diameter of the stent is 20 French (Fr) following delivery \[[@CR12]\]. The aforementioned characteristics render this product adequate in the treatment of VUAS.

Surgical procedure {#Sec8}
------------------

The endoscopic insertion of the Memokath^®^045 stent was undertaken in 2 stages.

### Stage 1---urethral dilation {#Sec9}

The patient was placed in lithotomy position and a rigid cystoscopy was performed with a 22-Fr cystoscope. Visualization of the Ureteric Orifices (UO) was required. If the UO is very close to the bladder neck, the insertion of the Memokath^®^045 stent is contraindicated. The urethra was examined, and the stricture was dilated or incised to a minimum diameter of 30 Fr to allow for the delivery of the Memokath^®^045 stent. Dilation was carried out via 'S'-shaped dilators. In difficult strictures, incision and vaporisation of the bladder neck scar tissue was required with a roller ball. Haemostasis is carefully achieved. The stricture length was measured accurately using the graduations on the cystoscope to ascertain the required stent length. Finally, a 22-Fr urethral catheter was left in situ and the patient was discharged.

### Stage 2---Memokath^®^045 stent insertion {#Sec10}

After 2 weeks, when the pain, inflammation and bleeding have settled, the second procedure is undertaken. A repeat cystoscopy was performed and the exact stricture length re-measured. The required Memokath^®^045 stent with the best fit is chosen (stents are available in 5, 10, 20 mm lengths). The protective cover of the Memokath^®^045 stent was removed and the mandrel inside the sheath was replaced by a 30° scope. Once the Memokath^®^045 stent was positioned at the exact stricture site, warm 70 °C sterile water was infused through the proximal connector on the collar of the sheath, causing the expansion of the proximal end of the stent. Further, warm water is infused through the distal connector which expands the distal end. Infusion is continued in both connectors and the stent is visualized by fluoroscopy. When the entire stent is expanded, the scope with the inner sheath is withdrawn under vision holding the outer sheath to prevent stent migration.

Most patients were discharged on the same day of the procedure. Intra-operative gentamicin was given. Patients received a three-day prophylactic antibiotic regime, along with analgesia as required.

### Memokath^®^045 stent removal {#Sec11}

12 months after insertion, the Memokath^®^045 stent was removed. The Memokath^®^045 stent was irrigated via cold sterile water at a temperature of 10--15 °C using a 22-Fr cystoscope. The cold water shrinks the Memokath^®^045 stent and it was removed with biopsy forceps. The bladder was re-scoped to ensure that the patient had a patent and wide bladder neck and to look for stones. The patients were discharged on the same day with a three-day post-procedure course of prophylactic antibiotics.

Follow-up assessment and data collection {#Sec12}
----------------------------------------

Perioperative data such as operation time and Memokath^®^045 stent length were recorded.

Patients were followed up 4--6 weeks post-procedure, then every 6 months for the first year, and then once yearly. Post-procedure assessment included International Prostate Symptom Score (IPSS), quality of life (QoL), incontinence (number of pads), flow rates and post-voiding residuals. Complications and Memokath^®^045 stent failure or removal were also recorded.

Statistical analysis {#Sec13}
--------------------

Statistical analysis was performed using SPSS 15.0 and microsoft excel. Results for continuous variables were described as Mean and Standard Deviation, whilst categorical variables were described as the number of patients and percentages.

Results {#Sec14}
=======

Pre-operative results {#Sec15}
---------------------

30 patients were reviewed in this data set, with a median age of 62 and an inter-quartile range of 54--72 (Table [7](#Tab7){ref-type="table"}). 24 (80%) patients had primary prostatectomy, of which 16 (53%) was robot assisted; 3 (10%) was laparoscopic, 1 (3%) was open and 4 (13%) had adjuvant radiotherapy. 6 (20%) patients had sRARP (Table [2](#Tab2){ref-type="table"}). All 30 patients had received two attempts at endoscopic dilation and clean intermittent catheterisation. The mean time between prostatectomy surgery and Memokath^®^045 Stent insertion was 13 months (Table [3](#Tab3){ref-type="table"}). 20 (67%) patients were catheter dependent for voiding, whilst 10 (33%) were catheter independent (Table [4](#Tab4){ref-type="table"}) but with a significantly obstructed voiding pattern of *Q*~max~ 6 mls/s (± 2) and post void residual (PVR) of 176 mls (± 52) (Table [7](#Tab7){ref-type="table"}).

Intra-operative results {#Sec16}
-----------------------

In 26 (87%) patients, the 5-mm Memokath^®^045 stent was used, 3 (10%) required 10 mm and 1 (3%) required 20 mm who had previous brachytherapy and anastomotic displacement (Table [5](#Tab5){ref-type="table"}). The mean operation time for stage 1 was 22 (± 6) mins and for stage 2 was 12 (± 4) mins. All patients went home the same day (Table [6](#Tab6){ref-type="table"}).

Post-operative results {#Sec17}
----------------------

Median time of follow-up was 3.6 years (2.2--4.8), with all patients completing a minimum of 1-year follow-up.

The results show an improvement in International Prostate Symptom Score (IPSS) from an average of 28 pre-operation to 10, 12 months after the Memokath^®^045 stent removal. IPSS Quality of Life score also improved from 5 (unhappy with symptoms) to 2 (mostly satisfied with symptoms). The *Q*~max~ and PVR baseline was measured only for the ten patients who were catheter independent pre-operation. *Q*~max~ showed improvement from 6 to 14 mls/s and PVR improved from 176 mls to a negligible 22 mls (Table [7](#Tab7){ref-type="table"}).

Importantly, incontinence results showed at short-term follow-up of 3 months and medium-term follow-up of at least 12 months post removal, 93% of patients were fully continent with 100% of patients being fully or socially continent (Table [7](#Tab7){ref-type="table"}).

Note: In two patients, there was Memokath^®^045 stent removal due to failure; therefore, only 28 patients had the full follow-up.

Complications and failure {#Sec18}
-------------------------

2 (7%) patients suffered from dysuria, 2 (7%) patients had ejaculatory pain and 2 (7%) patients had temporary urge incontinence, they were all managed conservatively to good effect. In 2 (7%) patients, the Memokath^®^045 size was too long and overlapped the sphincter; so, the stents were replaced. In 1 (3%) patient, the stent migrated due to inappropriate urethral catheterisation and it was replaced operatively (Table [8](#Tab8){ref-type="table"}).

In 2 (7%) of patients, the stent failed and was removed but not replaced; one due to re-stricture through the stent and another due to stone formation causing retention (Table [9](#Tab9){ref-type="table"}).

In our series, we did not observe any other stricture recurrence or urinary retention. We also did not observe any urinary tract infections.

Discussion {#Sec19}
==========

This retrospective review is one of the few studies of the Memokath^®^045 stent in the literature, especially for the treatment of VUAS post prostatectomy. The limitations of this study include the retrospective nature, the limited number of patients involved and the unknown long-term follow-up results.

The surgical technique has a short operating time, it is easy to learn, and patients can go home the same day. The use of the Memokath^®^045 stent resulted in improved IPSS scores, quality of life and flow rate. Continence results showed that 93% of our patients achieved full continence after a minimum 12-month follow-up, whilst the remaining 7% achieved social continence. 21% of our patients encountered minor complications (Clavien grade 1 or 2), which were successfully managed conservatively. 10% of patients required a re-operation due to inadequate stent size or stent migration. Additionally, in 7%, the stent failed and was removed and not replaced due to re-stricture and stone formation.

Overall, the use of the Memokath^®^045 stent for the management of VUAS in patients who have previously failed endoscopic dilation is a novel and successful technique. It is less invasive than other techniques such as bladder neck reconstruction and urinary diversion and provides superior patency results. Comparative options such as bladder neck reconstruction have been shown to provide successful management in approximately 60--93% of patients. In addition, bladder neck reconstruction is a major complex procedure and has a significant risk of incontinence, resulting in the need for artificial urinary sphincter insertion \[[@CR8], [@CR9], [@CR13]\]. Furthermore, urinary diversion is also a major procedure which whilst achieving urinary flow results in worse patient satisfaction outcomes. Comparatively, our series shows that in 93% of patients, the Memokath^®^045 stent was successful with minimal complications and excellent post-operation continence rates.

We would advocate the consideration and utilization of the Memokath^®^045 stent in patients with intractable VUAS following radical prostatectomy.

Appendix {#Sec20}
========

See appendix Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"}, [8](#Tab8){ref-type="table"}, [9](#Tab9){ref-type="table"}.Table 1Number and age of patientsNumber of patients30Patient age (Median + IQR)62 (50--73)Table 2Cause of strictureCause of strictureNumber of cases (%)Radical prostatectomy20 (67%) Robot-assisted16 (53%) Laparoscopic3 (10%) Open1 (3%)Radical prostatectomy + adjuvant radiotherapy4 (13%)Salvage prostatectomy6 (20%) Post radiotherapy1 (3%) Post brachytherapy1 (3%) Post HIFU4 (13%)Table 3Time to insertionTime from prostatectomy to Memokath^®^045 insertion (months) (mean + SD)13 (± 3)Table 4Severity of LUTS prior to Memokath^®^045 insertionCatheter dependent20 (67%)Non-catheter dependent10 (33%)Table 5Memokath^®^045 length5 mm26 (87%)10 mm3 (10%)20 mm1 (3%)Table 6Operation time and length of stayStage 1 Operation time (mins) (mean + SD)22 (± 6) Length of stay (DAYS) (mean)1Stage 2 Operation time (MINS) (mean + SD)12 (± 4) Length of stay (days) (mean)1Table 7Follow-Up OutcomesBaseline3 months post-Memokath^®^045 insertion3 months post-Memokath^®^045 removalMinimum 12 months post-Memokath^®^045 removalIPSS28 (± 4)12 (± 3)12 (± 4)10 (± 4)IPSS-QoL5 (± 1)2 (± 1)2 (± 1)2 (± 1)*Q*~max~ (mls/s)6 (± 2)16.8 (± 4.5)14.2 (± 6.8)14 (± 10.2)PVR (mls)176 (± 52)16 (± 6)20 (± 8)22 (± 12)No. of pads used/day (%) 024 (86%)26 (93%)26 (93%) 1--22 (7%)2 (7%)2 (7%) \> 22 (7%)00Table 8Type of complicationsTypeNumber of patients (%)Clavien--DindoManagementDysuria2 (7)1Conservative, analgesiaEjaculatory pain2 (7)1Conservative, analgesiaTemporary urge incontinence2 (7)2Conservative, anticholinergicInadequate Memokath^®^045 size2 (7)3aRe-operation and replacementMemokath^®^045 migration1 (3)3aRe-operation and replacementTable 9Type of failure---resulting in Memokath^®^045 stent removalTypeNumber of patients (%)RE-stricture through MEMOKATH^®^045 stent1 (3)Stone formation1 (3)
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